NDA 022090 · Bayer Hlthcare
Eovist
Gadoxetate Disodium · Intravenous
NovelLast checked: Nov 20, 2026Latest source record: Feb 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2008
Jul 3, 2008
Approved uses
2
Original approval plus efficacy supplements
Registered trials
14
2 Phase 3, 2 recruiting
FAERS reports
441
244 serious, 2 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS Risk Associated with Intrathecal Use Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. EOVIST is not approved for intrathecal use [see Warnings and Precautions (5.1) ]. Nephrogenic Systemic Fibrosis GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of EOVIST in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs. The risk for NSF appears highest among patients with: Chronic, severe kidney disease (GFR < 30 mL/min/1.73m 2 ), or Acute kidney injury. Screen...
What it is approved for
From the label in effect Mar 2, 2026.
EOVIST is indicated for use in magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adult and pediatric patients, including term neonates, with known or suspected focal liver disease. EOVIST is a gadolinium-based contrast agent indicated for use in magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adult and pediatric patients, including term neonates, with known or suspected focal liver disease. ( 1 )
Mechanism: Gadoxetate is a paramagnetic molecule that develops a magnetic moment when placed in a magnetic field. The magnetic moment alters the relaxation rates of water protons in its vicinity in the body, leading to an increase in signal intensity (brightness) of tissues. Gadoxetate is selectively taken up by hepatocytes, resulting in increased signal intensity in liver tissue.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 27, 2015 Supplement 11 · Efficacy LabelLetter
- Jul 3, 2008 Original approval · Type 1 - New Molecular Entity NovelLabelReviewPediatric Medical Review
2 products under this application
- EOVIST · GADOXETATE DISODIUM 2.72145GM/15ML (181.43MG/ML) · SOLUTION, INTRAVENOUS · Prescription
- EOVIST · GADOXETATE DISODIUM 1.8143GM/10ML (181.43MG/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Gadoxetate Disodium" as an intervention, any sponsor and status, largest first.
GuerbetIndustry
NCT04373564 · 2,076 participants (planned) · Start Mar 24, 2021 · Primary completion Dec 31, 2028
Drug: Gadoxetate disodium; Gadobenate dimeglumine and 4 more · For: Motor Function; Cognitive Function; Contrast Media
Sites: Scottsdale, Arizona; New Haven, Connecticut; Chicago, Illinois · 51 sites in all
BayerBayer (BAYRY)
NCT00908596 · 357 participants · Start May 2009 · Primary completion Jul 2013
Drug: Gadoxetic acid disodium (Primovist, BAY86-4873) · For: Contrast Media
Sites: Los Angeles, California; Jacksonville, Florida; Honolulu, Hawaii · 47 sites in all
- Efficacy and Safety of Primovist in Chinese PatientsPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00526188 · 234 participants · Start Aug 2007 · Primary completion Aug 2008
Drug: Gadoxetic Acid Disodium (Primovist, BAY86-4873) · For: Known or Suspected Focal Liver Lesions
Sites: Nanjing, China; Suzhou, China; Xi'an, China · 6 sites in all
- Contrast-enhanced MRI in Detecting Benign and Malignant Liver LesionsActive, not recruiting
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT02156739 · 100 participants · Start Oct 13, 2014 · Primary completion Jun 1, 2028
Drug: Gadobutrol; Gadoxetate Disodium · For: Hepatocellular Carcinoma; Liver and Intrahepatic Bile Duct Disorder; Metastatic Malignant Neoplasm in the Liver and 1 more
Sites: Houston, Texas
Mayo ClinicAcademic, hospital or other
NCT06905054 · 80 participants (planned) · Start Apr 15, 2025 · Primary completion Mar 30, 2028
Drug: Fenofibrate (drug) · For: Primary Sclerosing Cholangitis; Liver Transplant, Complications; PSC and 1 more
Sites: Scottsdale, Arizona
University of CincinnatiAcademic, hospital or other
NCT03960788 · 50 participants (planned) · Start Jan 2, 2018 · Primary completion Jan 2, 2020
Drug: Gadoxetate Sodium · For: Cancer of the Prostate; Castration-resistant Prostate Cancer
Sites: Cincinnati, Ohio
Duke UniversityAcademic, hospital or other
NCT02431598 · 44 participants · Start Jun 2015 · Primary completion Sep 2015
Drug: gadoxetate disodium; gadoterate dimeglumine and 1 more · For: Transient Severe Arterial Phase Motion
Sites: Durham, North Carolina
University of Southern CaliforniaAcademic, hospital or other
NCT02578602 · 26 participants · Start Oct 2010 · Primary completion Nov 2014
Drug: Gadoxetate Disodium · For: Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage 0 Adult Hepatocellular Carcinoma and 6 more
Sites: Los Angeles, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- rash160
- pain155
- paraesthesia154
- arthralgia153
- burning sensation153
- hypoaesthesia153
- muscle spasms153
- gadolinium deposition disease152
- injury152
- asthenia150
- confusional state150
- fatigue150
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 5 |
| 2009 | 16 |
| 2010 | 40 |
| 2011 | 47 |
| 2012 | 23 |
| 2013 | 19 |
| 2014 | 20 |
| 2015 | 14 |
| 2016 | 18 |
| 2017 | 14 |
| 2018 | 14 |
| 2019 | 165 |
| 2020 | 7 |
| 2021 | 8 |
| 2022 | 5 |
| 2023 | 10 |
| 2024 | 8 |
| 2025 | 4 |
| 2026 | 4 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Eovist (Gadoxetate Disodium) · HCPCS A9581
2024 spending
$1.3M
Beneficiaries
7,513
9,428 claims
Per beneficiary
$173
2024 ASP limit $14.74 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $998,812 |
| 2021 | $1,117,691 |
| 2022 | $1,152,165 |
| 2023 | $1,199,615 |
| 2024 | $1,301,496 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Clinical usefulness of multiple arterial-phase images in gadoxetate disodium-enhanced magnetic resonance imaging: a systematic review and meta-analysis.
Hong S, Choi SH, Hong SB, et al. · Eur Radiol 2022 · Meta-Analysis, Systematic Review
- Functional image-guided stereotactic body radiation therapy planning for patients with hepatocellular carcinoma.
Tsegmed U, Kimura T, Nakashima T, et al. · Med Dosim 2017 · Clinical Trial
- Diagnostic performance of CT, gadoxetate disodium-enhanced MRI, and PET/CT for the diagnosis of colorectal liver metastasis: Systematic review and meta-analysis.
Choi SH, Kim SY, Park SH, et al. · J Magn Reson Imaging 2018 · Meta-Analysis, Systematic Review
- Gadoxetate-disodium-enhanced magnetic resonance imaging for liver fibrosis staging: a systematic review and meta-analysis.
Li X, Liu H, Wang R, et al. · Clin Radiol 2020 · Meta-Analysis, Systematic Review
- Gd-EOB-DTPA-enhanced magnetic resonance imaging for focal liver lesions in Chinese patients: a multicenter, open-label, phase III study.
Zeng MS, Ye HY, Guo L, et al. · Hepatobiliary Pancreat Dis Int 2013 · Clinical Trial, Phase III, Multicenter Study
- Improved detection of hypervascular liver lesions with CAIPIRINHA-Dixon-TWIST-volume-interpolated breath-hold examination.
Kazmierczak PM, Theisen D, Thierfelder KM, et al. · Invest Radiol 2015 · Clinical Trial
Sponsor: Bayer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.